Today, for example, Viking Therapeutics (VKTX) rocketed about $16 higher – and could easily see higher highs.
All after the company announced it was speeding up the development of its weight loss pill. Better, as noted by Barron’s, “The shortened timeline for the clinical testing of the shot makes Viking an even more ripe target for one of the big pharma firms looking to snap up an obesity drug of their own.”